Loading clinical trials...

Azithromycin in the Treatment of M. Avium Complex Lung Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Azithromycin in the Treatment of M. Avium Complex Lung Disease

Open, Noncomparative Trial of Azithromycin in the Treatment of M.Avium Complex (MAC) Lung Disease

NCT00599079•The University of Texas Health Science Center at Tyler

Summary

To determine the safety and efficacy of azithromycin in the treatment of lung infection with M.avium complex and M. abscessus lung disease.

Detailed Description

To study the safety and efficacy of azithromycin in combination treatment for M. abscessus and MAC lung disease

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

•Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; abnormal CXR consistent with M. avium lung disease; absence of other lung pathogens (except for the coexistence of M. abscessus).
•Age 18 and older
•Pretreatment isolate of M. avium complex available for MIC determination

Locations (1)

The University of Texas Health Science Center at Tyler

Tyler, Texas, United States

Key Dates

Start Date

February 1, 1993

Primary Completion Date

May 1, 2008

Completion Date

May 18, 2017

Last Updated

May 23, 2017

Enrollment

ACTUAL participants

Conditions

Mycobacterium Avium Complex Lung Disease

Interventions

Azithromycin

DRUG